{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-134767","form_type":"8-K","ticker":"SCLX","cik":"0001820190","company_name":"Scilex Holding Co","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.825762+00:00","generated_at":"2026-05-29T05:15:19.917180+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Scilex forms JV to develop Phase 2 oral KDS2010 for obesity and Alzheimer's","bullets":["Scilex contributes $50M of Semnur stock for controlling stake in Scilex Bio JV; IPMC holds 40%.","NeuroBiogen grants Scilex Bio exclusive worldwide license to KDS2010 for all indications.","KDS2010 is a reversible MAO-B inhibitor; Phase 1 shows favorable safety; Phase 2 ongoing in obesity and Alzheimer's.","Obesity drug market forecast ~$150B by early 2030s; Alzheimer's market >$15B by 2030."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-134767","json":"https://secwatch.observer/filing/0000950170-24-134767.json","markdown":"https://secwatch.observer/filing/0000950170-24-134767.md","text":"https://secwatch.observer/filing/0000950170-24-134767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1820190/000095017024134767/0000950170-24-134767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1820190/000095017024134767/sclx-20241210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:15:19.917180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}